ABL1 and leukemia: An interesting example that empathizes the clinical relevance of PTP and PTK double targeting has been demonstrated by Lai et al. (2018) in the context of BCR/ABL positive leukemia patients who experienced resistance to tyrosine kinase inhibitors (TKIs).